The two synthetic cannabinoid compounds 4′‐F‐CBD and HU‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes
Open Access
Abstract
To study the anti‐inflammatory potential of the two synthetic cannabinoids 4′‐F‐CBD and HU‐910, we used post‐natal brain cultures of mouse microglial cells and astrocytes activated by reference inflammogens. We found that 4′‐F‐CBD and HU‐910 efficiently curtailed the release of TNF‐α, IL‐6, and IL‐1β in microglia and astrocytes activated by the bacterial Toll‐Like Receptor (TLR)4 ligand LPS. Upon LPS challenge, 4′‐F‐CBD and HU‐910 also prevented the activation of phenotypic activation markers specific to microglia and astrocytes, that is, Iba‐1 and GFAP, respectively. In microglial cells, the two test compounds also efficiently restrained LPS‐stimulated release of glutamate, a non‐cytokine inflammation marker for these cells. The immunosuppressive effects of the two cannabinoid compounds were concentration‐dependent and observable between 1 and 10 μM. These effects were not dependent on cannabinoid or cannabinoid‐like receptors. Both 4′‐F‐CBD and HU‐910 were also capable of restraining the inflammogenic activity of Pam3CSK4, a lipopeptide that activates TLR2, and of BzATP, a prototypic agonist of P2X7 purinergic receptors, suggesting that these two cannabinoids could exert immunosuppressive effects against a variety of inflammatory stimuli. Using LPS‐stimulated microglia and astrocytes, we established that the immunosuppressive action of 4′‐F‐CBD and HU‐910 resulted from the inhibition of ROS produced by NADPH oxidase and subsequent repression of NF‐κB‐dependent signaling events. Our results suggest that 4′‐F‐CBD and HU‐910 may have therapeutic utility in pathological conditions where neuroinflammatory processes are prominent.Keywords
This publication has 67 references indexed in Scilit:
- Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as AntioxidantsMolecules, 2013
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ InvolvementPLOS ONE, 2011
- A new cannabinoid CB2 receptor agonist HU‐910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injuryBritish Journal of Pharmacology, 2011
- Pharmacological characterization of GPR55, a putative cannabinoid receptorPharmacology & Therapeutics, 2010
- Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomasGlia, 2010
- Emerging strategies for exploiting cannabinoid receptor agonists as medicinesBritish Journal of Pharmacology, 2009
- Apocynin: Molecular AptitudesMediators of Inflammation, 2008
- GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activationBritish Journal of Pharmacology, 2004
- Astrocytes protect neurons from neurotoxic injury by serum glutamateGlia, 1998
- Interactions ofΔ 11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographyCellular and Molecular Life Sciences, 1981